| Literature DB >> 32269654 |
Arkaitz Garbisu-Hualde1, Jordan Santos-Concejero1.
Abstract
This review aimed to analyse factors that limited performance in ultra-marathons and mountain ultra-marathons. A literature search in one database (PubMed) was conducted in February 2019. Quality of information of the articles was evaluated using the Oxford´s level of evidence and the Physiotherapy Evidence Database (PEDro) scale. The search strategy yielded 111 total citations from which 23 met the inclusion criteria. Twenty one of the 23 included studies had a level of evidence 2b (individual cohort study), while the 2 remaining studies had a level of evidence of 5 (expert opinion). Also, the mean score in the PEDro scale was 3.65 ± 1.61, with values ranging from 0 to 7. Participants were characterised as experienced or well-trained athletes in all of the studies. The total number of participants was 1002 (893 men, 86 women and 23 unknown). The findings of this review suggest that fatigue in ultra-endurance events is a multifactorial phenomenon that includes physiological, neuromuscular, biomechanical and cognitive factors. Improved exercise performance during ultra-endurance events seems to be related to higher VO2max values and maximal aerobic speed (especially during submaximal efforts sustained over a long time), lower oxygen cost of transport and greater running experience.Entities:
Keywords: VO2max; endurance; fatigue; performance; trail running
Year: 2020 PMID: 32269654 PMCID: PMC7126261 DOI: 10.2478/hukin-2019-0102
Source DB: PubMed Journal: J Hum Kinet ISSN: 1640-5544 Impact factor: 2.193
Figure 1Flow chart of the search strategy
Physiotherapy Evidence Database (PEDro) ratings and Oxford evidence levels of the included studies.
| PEDro ratings* | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Total | Evidence level |
| Sansoni et al. (2017) | yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2b |
| Bonsigniore et al. (2017) | yes | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 2b |
| yes | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 2b | |
| yes | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 2b | |
| yes | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 2b | |
| yes | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 7 | 2b | |
| no | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 2b | |
| yes | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 5 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 2b | |
| no | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | |
| no | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | |
| yes | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 2b | |
| yes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 2b | |
Items in the PEDro scale: 1 = eligibility criteria were specified; 2 = subjects were randomly allocated to groups; 3 = allocation was concealed; 4 = the groups were similar at baseline regarding the most important prognostic indicators; 5 = blinding of all subjects; 6 = blinding of all therapists who administered the therapy; 7 = blinding of all assessors who measured at least 1 key outcome; 8 = measures of 1 key outcome were obtained from 85% of subjects initially allocated to groups; 9 = all subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least 1 key outcome were analysed by “intention to treat”; 10 = the results of between-group statistical comparisons are reported for at least 1 key outcome; 11 = the study provides both point measures and measures of variability for at least 1 key outcome.
Included studies
| Study | Number (M/F) | Age | Level | Main Outcome |
|---|---|---|---|---|
| Sansoni et al. (2017) | 20 (20/0) | 38.8 ± 7.2 | E | Bone turnover |
| Bonsigniore et al. (2017) | 21 (15/6) | 39.8 ± 8.3 | WT | Arterial compliance |
| 19 (16/3) | 41 ± 9 | WT | Electro-mechanical delay | |
| 11 (11/0) | 42 ± 11 | WT | Cardiac disfunction and cTnT | |
| 26 (26/0) | 41 ± 10 | WT | Cardiac disfunction and cTnT | |
| 22 (22/0) | 46.1 ± 10.8 | WT | Cardiac and muscle biomarkers | |
| 109 (98/11) | 35 ± 8.4 | WT | Macronutrient and water intake | |
| 53 (41/12) | 36.6 ± 8.0 | WT | Macronutrient and water intake | |
| 170 (158/12) | 40 (M) / 35 (F) | WT | Gastro-intestinal disturbance | |
| 21 (16/5) | 38.5 ± 9.6 | WT | COL5A1 | |
| 32 (25/7) | 42.5 ± 9.3 | WT | COL5A1 | |
| 18 (10/8) | 40.6 ± 9.2 | WT | COL5A1 | |
| 11 (11/0) | 40.5 ± 8.4 | E | Metabolic cost of transport | |
| 25 (25/0) | 38.2 ± 7.1 | WT | Strength training and Economy | |
| 23 (17/6) | 40.2 ± 7.3 | WT | Physiological profile | |
| 26 (26/0) | 41.7 ± 9.5 | WT | Performance factors | |
| 11(6/5) | 43 ± 10 | E | Immunoglobulin types | |
| 95 (95/0) | 44.5 ± 10.0 | WT | Hyponatremia | |
| 157 (157/0) | 45.7 ± 9.6 | E | Hyponatremia | |
| (Unkown) 23 | 28 ± 1 / 25 ± 4 | E / N | Serum Biochemical parameters | |
| 11 (8/3) | 43.7 ± 8.6 | WT | Plasma B-6 vitamin | |
| 9 (9/0) | 41.6 ± 5.9 | WT | Knee extensor fatigue | |
| 30 (30/0) | 43 ± 8.6 | WT | Cognitive function | |
| - | - | - | - | |
| Millet and | - | - | - | - |
| 20 (19/1) | 40.8 ± 11.7 | WT | Muscle cramps | |
| 29 (23/6) | 40.2 ± 9.2 | WT | Muscle cramps | |
| 10 (8/2) | 38.2 ± 7.9 | WT | Respiratory muscle fatigue |
WT = Well-trained; E = Experienced; N = Novice